– USA, CA – Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of veteran biotech executive Dr Joanne Viney, Ph.D., to its board as an independent director.
“Jo is an accomplished executive with an impressive track record of scientific achievement and drug development,” said President and CEO, Dr Jerry McMahon. “Her expertise as an immunologist will be helpful to the company as we continue to advance our TriTAC T cell engaged platform.”
Current board members, Luke Evnin, Ph.D, and Patrick Baeuerle, Ph.D., will be stepping down from the board.
“In addition, I would also like to express my deepest gratitude to Patrick Baeuerle and Luke Evnin, who were instrumental in founding Harpoon in 2015, for their years of service, dedication, impactful contributions, and valuable insights that both of them have brought to Harpoon,” said Jerry McMahon.
“In the relatively short time since Harpoon was launched, the company has created a significant clinical pipeline of products that have the potential to impact human diseases, and I am proud to leave the Harpoon board in capable hands to execute against the ambitious vision for the company and to deliver value to its stakeholders,” said Luke Evnin, Ph.D., Founder and Managing Director of MPM Capital.
“While I am leaving the Harpoon board, I am pleased to continue to advise the company on scientific matters as the company executes its founding mission to bring T cell engagers to cancer patients with solid tumor malignancies,” said Patrick Baeuerle, Ph.D., Executive Partner at MPM Capital and CSO of Cullinan Oncology.
Following these changes, Harpoon’s board will be composed of nine directors.
About Dr Jo Viney
Dr. Viney is an entrepreneurial scientist and experienced biotech executive with deep autoimmune and inflammatory disease expertise. Dr. Viney currently serves as President, CSO and Co-founder of Pandion Therapeutics, a privately held startup drug discovery and development company focused on developing modular biologics for regulating autoimmunity and inflammatory disease. Previously, Dr. Viney worked at Biogen where she began as Vice President, Immunology Research and was responsible for building and advancing the company’s immunology portfolio before moving on to become Senior Vice President, Drug Discovery and a member of the senior R&D leadership team. Previous roles include Director of Inflammation Research at Amgen as well as Director, Department of Autoimmunity and Inflammation at Immunex.
“I am excited to join the board of Harpoon and am looking forward to contributing to the company’s immuno-oncology efforts and impacting the lives of people with cancer,” said Dr. Viney.
She received a Ph.D. in immunology from the University of London, St. Bartholomew’s Hospital Medical School and a B.Sc. in biophysical science from the University of East London. Dr. Viney is a member of the Board of Directors of Finch Therapeutics and Quench Bio, and is a member of the Scientific Advisory Board for HotSpot Therapeutics.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1 trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and Harpoon plans to initiate a Phase 1/2a trial in the second half of 2020.
For more information : https://www.harpoontx.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.